Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aminoglycoside ototoxicity.

Duane E Bates1

  • 1Clinical Pharmacist, Internal Medicine, Foothills Medical Centre, Calgary, Canada. duane.bates@calgaryhealthregion.ca

Drugs of Today (Barcelona, Spain : 1998)
|May 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.

The Annals of pharmacotherapy·2006
Same author

Rhabdomyolysis and hepatotoxicity in a female body builder.

The Journal of trauma·2006
Same author

Ototoxicity induced by gentamicin and furosemide.

The Annals of pharmacotherapy·2002
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

New insights into aminoglycoside ototoxicity reveal genetic predispositions and the role of reactive oxygen species. Concurrent antioxidant or iron chelator therapy may reduce drug-induced hearing loss.

Area of Science:

  • Ototoxicity research
  • Pharmacology
  • Genetics

Background:

  • Aminoglycoside antibiotics are crucial for treating bacterial infections but can cause ototoxicity (hearing and balance damage).
  • Recent research has improved understanding of risk factors, mechanisms, and prevention strategies for aminoglycoside-induced ototoxicity.
  • Higher doses of aminoglycosides administered once daily intravenously show clinical efficacy without increased ototoxicity compared to traditional methods.

Purpose of the Study:

  • To review current knowledge on aminoglycoside ototoxicity, including genetic risk factors and preventative measures.
  • To highlight the role of reactive oxygen species in aminoglycoside-induced hearing loss.
  • To discuss the potential of antioxidant and iron chelator therapies in mitigating ototoxicity.

Main Methods:

Related Experiment Videos

  • Literature review of studies published over the last 10 years on aminoglycoside ototoxicity.
  • Analysis of clinical data comparing different aminoglycoside administration regimens.
  • Review of experimental animal studies investigating the mechanisms of ototoxicity and potential interventions.

Main Results:

  • Genetic mutations, specifically an A-to-G substitution in mitochondrial ribosomal ribonucleic acid (RNA) at position 1555 and a thymidine deletion in the 12s ribosomal RNA gene, are linked to increased susceptibility to aminoglycoside ototoxicity.
  • Experimental data strongly suggest that reactive oxygen species are key mediators of aminoglycoside-induced ototoxicity.
  • Animal studies indicate that co-administration of antioxidant or iron chelator therapy with aminoglycosides can decrease drug-induced hearing loss.

Conclusions:

  • Understanding genetic predispositions and the role of reactive oxygen species is crucial for preventing aminoglycoside ototoxicity.
  • Once-daily high-dose intravenous aminoglycoside administration is a safe and effective regimen.
  • Antioxidant and iron chelator therapies show promise as preventative strategies against aminoglycoside-induced hearing damage.